Holen Sie sich die Stockscreener-App
12.88
1.45%
-0.19
Vorhandelsmarkt:
13.08
0.20
+1.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$13.07
Offen:
$13.07
24-Stunden-Volumen:
5.01M
Relative Volume:
1.64
Marktkapitalisierung:
$1.27B
Einnahmen:
$669.43M
Nettoeinkommen (Verlust:
$-609.36M
KGV:
-2.1094
EPS:
-6.1061
Netto-Cashflow:
$-507.20M
1W Leistung:
-9.99%
1M Leistung:
-51.38%
6M Leistung:
-40.97%
1J Leistung:
-56.31%
1-Tages-Spanne:
$12.73
$13.22
1-Wochen-Bereich:
$12.73
$14.70
52-Wochen-Spanne:
$12.73
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
12.88 | 1.41B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
513.26 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.61 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.69 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.62 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
195.92 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
Technical Reactions to RARE Trends in Macro Strategies - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx’s GTX-102 failure erases pipeline sales expectations - spglobal.com
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares By Investing.com - Investing.com South Africa
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares - Investing.com
Ultragenyx (NASDAQ: RARE) exec sells 161 shares for RSU tax, keeps 69,146 - Stock Titan
$Ultragenyx Pharmaceutical (RARE.US)$ get ready - moomoo.com
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial - StocksToTrade
Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win - timothysykes.com
Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism - StocksToTrade
RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure - timothysykes.com
The Goldman Sachs Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
This week in charts: China deals, stock flatlines and Lilly’s M&A spree - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Rx Rundown: Eli Lilly, Ultragenyx, Novartis and more - Medical Marketing and Media
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharma Is Maintained at Overweight by Barclays - moomoo.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Hold" at Royal Bank Of Canada - MarketBeat
Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx: A 44% Crash After Trial Failure, Two Weeks After First Gene Therapy Approval - Kavout
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st
Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group - MarketBeat
Ultragenyx Pharma Cut to Market Perform From Outperform by William Blair - Moomoo
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist - Seeking Alpha
Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec - Pharmaceutical Executive
Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Pivotal Trial - finance.biggo.com
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder - MedCity News
Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE) - MarketBeat
Ultragenyx Weighs Future of Angelman Syndrome ASO After Phase III Trial Failure - GenomeWeb
Citigroup Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target - Benzinga
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $18.00 Price Target at TD Cowen - MarketBeat
Angelman wings clipped by Ultragenyx phase III bust - BioWorld News
Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial - BioPharm International
Ultragenyx mulls fate of rare disease programme on Phase III flop - Clinical Trials Arena
Ultragenyx stock downgraded after trial setback (RARE:NASDAQ) - Seeking Alpha
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? - Yahoo Finance
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - TradingView
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study - BioPharma Dive
Ultragenyx sinks as Phase 3 Angelman trial miss slams a key pipeline bet - Quiver Quantitative
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ultragenyx Pharmaceutical Inc-Aktie (RARE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Aug 03 '26 |
Sale |
24.92 |
1,900 |
47,348 |
92,562 |
| Horn Howard | Chief Financial Officer |
Aug 03 '26 |
Sale |
24.92 |
4,696 |
117,024 |
96,295 |
0.00%
4.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):